Sutro Biopharma Inc [STRO] stock is trading at $2.04, up 4.62%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The STRO shares have gain 7.94% over the last week, with a monthly amount drifted -28.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on May 08, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $12. Previously, Deutsche Bank started tracking the stock with Buy rating on November 09, 2023, and set its price target to $12. On October 06, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $10 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $8 on March 21, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on June 18, 2021, and assigned it a price target of $35. In a note dated December 03, 2020, Stifel initiated an Buy rating and provided a target price of $25 on this stock.
Sutro Biopharma Inc [STRO] stock has fluctuated between $1.70 and $6.13 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $2.04 at the most recent close of the market. An investor can expect a potential return of 537.25% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 160.96M for the trailing twelve months, which represents a drop of -49.66%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.81%, Pretax Profit Margin comes in at -0.67%, and Net Profit Margin reading is -0.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.97 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9700 points at the first support level, and at 1.8900 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1000, and for the 2nd resistance point, it is at 2.1600.
Ratios To Look Out For
For context, Sutro Biopharma Inc’s Current Ratio is 3.09. Also, the Quick Ratio is 3.09, while the Cash Ratio stands at 1.33. Considering the valuation of this stock, the price to sales ratio is 1.06, the price to book ratio is 1.51.
Transactions by insiders
Recent insider trading involved Vasquez Nicki, CHIEF PORT. STRAT & ALNCE OFCR, that happened on Jan 29 ’24 when 12185.0 shares were sold.
